Provention Bio, Inc. (Nasdaq: PRVB), a US-based biopharmaceutical company, announced on Thursday that it has named Rita Jain, MD as its new director.

Dr Jain has over two decades of experience in pharmaceutical development. Currently Dr Jain serves as a member of the supervisory board of AM Pharma.

Previously, Dr Jain has served as executive vice president, chief medical officer of ChemoCentryx, Inc., chief medical officer of Immunovant, Inc. and senior vice president and chief medical officer of Akebia Therapeutics, Inc. Dr Jain has also worked as vice president of Men's and Women's Health and Metabolic Development at AbbVie, Inc and in various leadership roles at Abbott Laboratories, including Divisional vice president. She has served in management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle, and has served as a faculty member at North Shore University Hospital in New York.

Wayne Pisano, chairman of the Provention Bio board, said, 'Rita brings extensive drug development experience to Provention Bio across a wide range of therapeutic areas including autoimmune and metabolic diseases. Rita's demonstrated track record in leading corporate strategy formulation and the execution of global, commercial programs makes her a strong addition as we look to expand the experience of our board to support this new, exciting chapter in the company's evolution. We look forward to Rita's governance, advice and counsel as we advance the commercial launch of TZIELD (teplizumab-mzwv) in the U.S. and move towards the establishment of a global franchise.'